By Dr Andrew On Wah Yam

Journal articles

Shekar S; Crumbaker M; Joshua A; Yam A; Stricker P; Yuen C; Ende D; Namdarian B; Thompson J; Kooner R; O'Neill G; Mo J; Sim HW; Hruby G; Kasraei F; Ho A; De Leon J, 2025, 'Real-world clinical outcomes of oligometastatic prostate cancer using SBRT: An Australian experience', Bjui Compass, 6, http://dx.doi.org/10.1002/bco2.70055

Crumbaker M; Shekar S; Lawrence MG; Goldstein LD; Yam AO; Downton T; Begbie S; Zielinski R; Fox W; Araiza N; Yousif J; Ratnayake L; Antonarakis ES; Denmeade SR; Joshua AM, 2025, 'A phase II single arm prospective study of high dose testosterone in combination with carboplatin chemotherapy in late line metastatic castrate-resistant prostate cancer (HIGH-TeCH study).', JOURNAL OF CLINICAL ONCOLOGY, 43, http://dx.doi.org/10.1200/JCO.2025.43.5_suppl.218

Pakiam JA; Nadua KD; Lin C; Hoh SY; Chew EM; Yam AKT; Teo JH; Ng ZM; Ganesan I; Chong CY; Thomas T, 2025, 'Childhood acute flaccid myelitis, including the first confirmed cases of enterovirus D68 myelitis, in Singapore and Southeast Asia', JOURNAL OF PAEDIATRICS AND CHILD HEALTH, 61, pp. 160 - 165, http://dx.doi.org/10.1111/jpc.16727

Azad AA; Bressel M; Tan H; Voskoboynik M; Suder A; Weickhardt AJ; Guminski A; Francis RJ; Saghebi J; Dhiantravan N; Joshua AM; Emmett L; Horvath L; Murphy DG; Hsiao E; Balakrishnar B; Lin P; Redfern A; Macdonald W; Ng S; Lee ST; Pattison DA; Nadebaum D; Kirkwood ID; Hofman MS; Akhurst T; Alipour R; Au L; Banks P; Emerson B; Hussain N; Haskali M; Lewin J; Linklater R; Kostos L; Kashyap R; Krishanth P; Kong G; Kumar A; Murphy D; Roselt P; Sandhu S; Scalzo M; Tran B; Wallace R; Spain L; Bourke H; Milton A; Russo D; Bills M; Chew C; Hsieh W; Crouch B; Smyth D; Pandelus S; Lam H; Gan C; Goh J; Scott A; Hafeez U; Ackermann U; Young K; Poon A; Pathmaraj K; Schembri G; Roach P; Bailey D; Hung T; Asad A; Hagan T; Watts J; Campbell E; Chua W; Pal A; Crumbaker M; Nguyen A; Yam A; Chen J; Ardolino L; Kongrak K; Ratnayake L, 2024, 'Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study', Lancet Oncology, 25, pp. 1267 - 1276, http://dx.doi.org/10.1016/S1470-2045(24)00440-6

Yam AO; Jakovija A; Gatt C; Chtanova T, 2024, 'Neutrophils under the microscope: neutrophil dynamics in infection, inflammation, and cancer revealed using intravital imaging', Frontiers in Immunology, 15, http://dx.doi.org/10.3389/fimmu.2024.1458035

Tang CQY; Yam AKT; Chew EM, 2024, 'Revisiting the terminology of end-to-side neurorrhaphy', JOURNAL OF HAND SURGERY-EUROPEAN VOLUME, 49, pp. 922 - 923, http://dx.doi.org/10.1177/17531934241238143

Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2023, 'Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy', Cancer Research, 83, pp. 1315 - 1328, http://dx.doi.org/10.1158/0008-5472.CAN-21-4025

Pathmanandavel S; Crumbaker M; Ho B; Yam AO; Wilson P; Niman R; Ayers M; Sharma S; Hickey A; Eu P; Stockler M; Martin AJ; Joshua AM; Nguyen A; Emmett L, 2023, 'Evaluation of 177Lu-PSMA SPECT Quantitation as a Response Biomarker within a Prospective 177Lu-PSMA-617 and NOX66 Combination Trial (LuPIN)', Journal of Nuclear Medicine, 64, pp. 221 - 226, http://dx.doi.org/10.2967/jnumed.122.264398

John N; Pathmanandavel S; Crumbaker M; Counter W; Ho B; Yam AO; Wilson P; Niman R; Ayers M; Poole A; Hickey A; Agrawal S; Perkins G; Kallinen A; Eslick E; Stockler MR; Joshua AM; Nguyen A; Emmett L, 2023, '177Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2) Predicts Short Progression-Free Survival for Patients Undergoing 177Lu-PSMA-I&T Therapy', Journal of Nuclear Medicine, 64, pp. 410 - 415, http://dx.doi.org/10.2967/jnumed.122.264677

Pathmanandavel S; Crumbaker M; Nguyen A; Yam AO; Wilson P; Niman R; Ayers M; Sharma S; Eu P; Martin AJ; Stockler MR; Joshua AM; Emmett L, 2023, 'The Prognostic Value of Posttreatment 68Ga-PSMA-11 PET/CT and 18F-FDG PET/CT in Metastatic Castration-Resistant Prostate Cancer Treated with 177Lu-PSMA-617 and NOX66 in a Phase I/II Trial (LuPIN)', Journal of Nuclear Medicine, 64, pp. 69 - 74, http://dx.doi.org/10.2967/jnumed.122.264104

Pathmanandavel S; Crumbaker M; Yam AO; Nguyen A; Rofe C; Hovey E; Gedye C; Kwan EM; Hauser C; Azad AA; Eu P; Martin AJ; Joshua AM; Emmett L, 2022, '177Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II Trial', Journal of Nuclear Medicine, 63, pp. 560 - 566, http://dx.doi.org/10.2967/jnumed.121.262552

Crumbaker M; Pathmanandavel S; Yam AO; Nguyen A; Ho B; Chan L; Ende JA; Rofe C; Kongrak K; Kwan EM; Azad AA; Sharma S; Pugh TJ; Danesh A; Keane J; Eu P; Joshua AM; Emmett L, 2021, 'Phase I/II Trial of the Combination of 177Lutetium Prostate specific Membrane Antigen 617 and Idronoxil (NOX66) in Men with End-stage Metastatic Castration-resistant Prostate Cancer (LuPIN)', European Urology Oncology, 4, pp. 963 - 970, http://dx.doi.org/10.1016/j.euo.2020.07.002

Emmett L; Pathmanandavel S; Crumbaker M; Rofe C; Yam AOW; Ho B; Chan WL; Sharma S; Keane J; Hickey AJ; Fullard K; Kongrak K; Ratnayake L; Violet JA; Azad A; Eu P; Nguyen A; Joshua AM, 2020, 'Updated results of a phase I/II prospective dose escalation trial evaluating safety and efficacy of combination ¹⁷⁷Lu PSMA 617 and idronoxil in men with mCRPC post androgen signalling inhibition and taxane chemotherapy (LuPIN trial).', Journal of Clinical Oncology, 38, pp. 5557 - 5557, http://dx.doi.org/10.1200/jco.2020.38.15_suppl.5557

Yam AO; Chtanova T, 2020, 'Imaging the neutrophil: Intravital microscopy provides a dynamic view of neutrophil functions in host immunity', Cellular Immunology, 350, http://dx.doi.org/10.1016/j.cellimm.2019.01.003

Emmett L; Pathmanandavel S; Nguyen A; Crumbaker M; Yam AOW; Chan WL; Fullard K; Ho B; Azad A; Joshua AM, 2020, 'Results of a phase I/II prospective dose-escalation trial evaluating safety and efficacy of combination 177LuPSMA-617 and NOX66 in men with mCRPC post androgen signalling inhibition and two lines of taxane chemotherapy (LuPIN trial).', Journal of Clinical Oncology, 38, pp. 120 - 120, http://dx.doi.org/10.1200/jco.2020.38.6_suppl.120

Yam AO; Chtanova T, 2019, 'The ins and outs of chemokine-mediated immune cell trafficking in skin cancer', Frontiers in Immunology, 10, http://dx.doi.org/10.3389/fimmu.2019.00386

Jiang J; Jais ISM; Yam AKT; McGrouther DA; Tay SC, 2017, 'A Biomechanical Comparison of Different Knots Tied on Fibrewire Suture', JOURNAL OF HAND SURGERY-ASIAN-PACIFIC VOLUME, 22, pp. 65 - 69, http://dx.doi.org/10.1142/S0218810417500113

Yam A; Barnet M; Mersiades A; Gao B; Kao S; Boyer M; Hui R; Nagrial A, 2017, 'P3.02c-055 Incidence and Grade of Pneumonitis in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with Anti-PD-1 Antibodies', Journal of Thoracic Oncology, 12, pp. S1308 - S1308, http://dx.doi.org/10.1016/j.jtho.2016.11.1850

Agrawal AK; Jais ISM; Chew EM; Yam AKT; Tay SC, 2016, 'Biomechanical investigation of "figure of 8' flexor tendon repair techniques', JOURNAL OF HAND SURGERY-EUROPEAN VOLUME, 41, pp. 815 - 821, http://dx.doi.org/10.1177/1753193416632640

Yam AK; Agrawal AK; Jais ISM; Tay SC, 2016, 'Re: Agrawal AK, Mat Jais IS, Chew EM, Yam AKT, Tay SC. Biomechanical investigation of 'figure of 8' flexor tendon repair techniques. J Hand Surg Eur. 2016, 41: 815-21.', JOURNAL OF HAND SURGERY-EUROPEAN VOLUME, 41, pp. 888 - 889, http://dx.doi.org/10.1177/1753193416666203

Tan B; Zammit NW; Yam A; Slattery RM; Walters SN; Malle E; Grey ST, 2013, 'Baculoviral inhibitors of apoptosis repeat containing (BIRC) proteins fine-tune TNF-induced nuclear factor êb and c-Jun N-terminal kinase signalling in mouse pancreatic beta cells', Diabetologia, 56, pp. 520 - 532, http://dx.doi.org/10.1007/s00125-012-2784-x

Chim H; Malkoc F; Tay S-C; Yam A; Teoh L-C, 2011, 'Technique of Olecranon Bone Grafting for Surgical Fixation of Scaphoid Fractures (vol 36A, pg 1220, 2011)', JOURNAL OF HAND SURGERY-AMERICAN VOLUME, 36A, pp. 1567 - 1567

Yam AO; Andresen D; Kesson AM; Isaacs D, 2009, 'Incidence of sterile cerebrospinal fluid pleocytosis in infants with urinary tract infection', Journal of Paediatrics and Child Health, 45, pp. 364 - 367, http://dx.doi.org/10.1111/j.1440-1754.2009.01502.x

Liuwantara D; Gunton J; Yam A; Walters S; Marino E; McShea A; Grey S, 2008, 'GENERATING ISLET ALLOGRAFT TOLERANCE BY BLOCKING NF-KB ACTIVATION AND PREVENTING APOPTOSIS.', Transplantation, 86, pp. 18 - 18, http://dx.doi.org/10.1097/01.tp.0000332732.20615.8f

Liuwantara D; Elliot M; Smith MA; Yam A; Walters SN; Marino E; McShea A; Grey S, 2006, 'Nuclear Factor-KB regulates beta-cell death - A critical role for A20 in beta-cell protection', Diabetes, 55, pp. 2491 - 2501

Ritchie AJ; Yam A; Tanabe K; Rice SA; Cooley MA, 2003, 'Modification of in viro and in vitro T- and B-Cell-Mediated Immune Responses by the Pseudomonas aeruginosa Quorum-Sensing Molecule N-(3-Oxododecanoyl)-L-Homoserine Lactone', Infection and Immunity, 71, pp. 4421 - 4431

Ritchie AJ; Yam AOW; Tanabe KM; Rice SA; Cooley MA, 2003, 'Modification of in vivo and in vitro T- and B-cell-mediated immune responses by the Pseudomonas aeruginosa quorum-sensing molecule N-(3-oxododecanoyl)-L-homoserine lactone', INFECTION AND IMMUNITY, 71, pp. 4421 - 4431, http://dx.doi.org/10.1128/IAI.71.8.4421-4431.2003

Conference Papers

Pathmanandavel S; Crumbaker M; Nguyen A; Yam A; Wilson P; Niman R; Ayers M; Sharma S; Hickey A; Eu P; Eslick E; Marquis H; Stockler M; Martin A; Joshua A; Emmett L, 2022, 'Serial whole-body 177Lu-SPECT quantitation for response assessment in metastatic, castration-resistant prostate cancer within a phase 1/2 trial of 177LuPSMA-617 plus NOX66 (LuPIN)', in JOURNAL OF NUCLEAR MEDICINE, SOC NUCLEAR MEDICINE INC, CANADA, Vancouver, presented at Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging (SNMMI), CANADA, Vancouver, 11 June 2022 - 14 June 2022

Emmett L; Pathmanandavel S; Crumbaker M; Rofe C; Yam AOW; Ho B; Chan WL; Sharma S; Keane J; Hickey AJ; Fullard K; Kongrak K; Ratnayake L; Violet JA; Azad A; Eu P; Nguyen A; Joshua AM, 2020, 'Updated results of a phase I/II prospective dose escalation trial evaluating safety and efficacy of combination Lu-177 PSMA 617 and idronoxil in men with mCRPC post androgen signalling inhibition and taxane chemotherapy (LuPIN trial).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 May 2020 - 31 May 2020, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000560368302400&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Emmett L; Pathmanandavel S; Nguyen A; Crumbaker M; Yam AOW; Chan WL; Fullard K; Ho B; Azad A; Joshua AM, 2020, 'Results of a phase I/II prospective dose-escalation trial evaluating safety and efficacy of combination 177LuPSMA-617 and NOX66 in men with mCRPC post androgen signalling inhibition and two lines of taxane chemotherapy (LuPIN trial)', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, CA, San Francisco, presented at Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO), CA, San Francisco, 13 February 2020 - 15 February 2020

Yam A; Barnet M; Mersiades A; Gao B; Kao S; Boyer M; Hui R; Nagrial A, 2017, 'Incidence and Grade of Pneumonitis in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with Anti-PD-1 Antibodies', in JOURNAL OF THORACIC ONCOLOGY, ELSEVIER SCIENCE INC, pp. S1308 - S1308, http://dx.doi.org/10.1016/j.jtho.2016.11.1850

Yam AO; Mersiadis A; Gao B; Hui R; Nagrial A, 2016, 'INCIDENCE AND GRADE OF PNEUMONITIS IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS TREATED WITH ANTI-PD1 ANTIBODIES', in ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, WILEY-BLACKWELL, pp. 71 - 72

Liuwantara D; Elliot M; Smith M; Walters SN; Marino E; Yam AO; Mcshea A; Grey ST, 2007, 'Nf-kb regulates b-cell death: A critical role for early immediate response genes in b-cell protection', in DIABETES, AMER DIABETES ASSOC, IL, Chicago, pp. A411 - A412, presented at 67th Annual Meeting of the American-Diabetes-Association, IL, Chicago, 22 June 2007 - 26 June 2007, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000246930202515&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Conference Abstracts

Pathmanandavel S; Crumbaker M; Yam AO; Nguyen A; Niman R; Wilson P; Sharma S; Ayers M; Eu P; Stockler MR; Martin AJ; Joshua AM; Emmett L, 2022, 'Quantifying molecular imaging patterns of treatment response or progression using a novel traffic light workflow within a prospective phase I/II trial of 1⁷⁷LuPSMA-617 and NOX66 (LuPIN).', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 40, presented at ASCO Genitourinary Cancers Symposium, ELECTR NETWORK, 17 February 2022 - 19 February 2022, http://dx.doi.org/10.1200/JCO.2022.40.6_suppl.166

Lau B; Crumbaker M; Yam AOW; Marastoni S; Luckhurst M; O'Grady A; Wouters B; Joshua AM, 2021, 'A phase I/II study of hydroxychloroquine and suba-itraconazole in men with biochemical relapse of prostate cancer (HITMAN-PC): Dose escalation results.', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 39, presented at ASCO Genitourinary Cancers Symposium (GU ASCO), ELECTR NETWORK, 11 February 2021 - 13 February 2021, http://dx.doi.org/10.1200/JCO.2021.39.6_suppl.114

Pathmanandavel S; Crumbaker M; Yam AOW; Rofe C; Ho B; Chan WL; Sharma S; Hickey AJ; Kongrak K; Ratnayake L; Kwan EM; Azad A; Eu P; Nguyen A; Joshua AM; Emmett L, 2021, 'Final results of a phase I/II prospective dose escalation trial evaluating safety and efficacy of combination 177Lu PSMA 617 and NOX66 in men with end-stage metastatic castration-resistant prostate cancer (LuPIN trial)', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, ELECTR NETWORK, Vol. 39, presented at ASCO Genitourinary Cancers Symposium (GU ASCO), ELECTR NETWORK, 11 February 2021 - 13 February 2021, http://dx.doi.org/10.1200/JCO.2021.39.6_suppl.103

Preprints

Yam A; Bailey J; Lin F; Jakovija A; Counoupas C; Triccas J; Gunzer M; Bald T; Grey S; Chtanova T, 2020, Microbial activation converts neutrophils into anti-tumor effectors, http://dx.doi.org/10.1101/2020.08.21.259051

Other

Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2025, Suppl video 1 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy, http://dx.doi.org/10.1158/0008-5472.30699957

Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2025, Suppl video 2 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy, http://dx.doi.org/10.1158/0008-5472.30699951

Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2025, Suppl video 3 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy, http://dx.doi.org/10.1158/0008-5472.30699948

Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2025, Suppl video 4 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy, http://dx.doi.org/10.1158/0008-5472.30699945

Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2025, Supplementary Data from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy, http://dx.doi.org/10.1158/0008-5472.30699942

Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2025, Supplementary Table 1 from Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy, http://dx.doi.org/10.1158/0008-5472.30699939

Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2024, Suppl video 1 from Neutrophil conversion to a tumor-killing phenotype underpins effective microbial therapy, http://dx.doi.org/10.1158/0008-5472.27027266.v1

Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2024, Suppl video 1 from Neutrophil conversion to a tumor-killing phenotype underpins effective microbial therapy, http://dx.doi.org/10.1158/0008-5472.27027266

Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2024, Suppl video 2 from Neutrophil conversion to a tumor-killing phenotype underpins effective microbial therapy, http://dx.doi.org/10.1158/0008-5472.27027263

Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2024, Suppl video 2 from Neutrophil conversion to a tumor-killing phenotype underpins effective microbial therapy, http://dx.doi.org/10.1158/0008-5472.27027263.v1

Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2024, Suppl video 3 from Neutrophil conversion to a tumor-killing phenotype underpins effective microbial therapy, http://dx.doi.org/10.1158/0008-5472.27027260

Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2024, Suppl video 3 from Neutrophil conversion to a tumor-killing phenotype underpins effective microbial therapy, http://dx.doi.org/10.1158/0008-5472.27027260.v1

Yam AO; Bailey J; Lin F; Jakovija A; Youlten SE; Counoupas C; Gunzer M; Bald T; Woodruff TM; Triccas JA; Goldstein LD; Gallego-Ortega D; Grey ST; Chtanova T, 2024, Suppl video 4 from Neutrophil conversion to a tumor-killing phenotype underpins effective microbial therapy, http://dx.doi.org/10.1158/0008-5472.27027257

Back to profile page